- Home
- ASAN vs ACAD Comparison
ASAN vs ACAD Comparison
Compare ASAN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASAN | ACAD |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ASAN | ACAD |
|---|---|---|
| Price | $7.26 | $24.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 22 |
| Target Price | $16.17 | ★ $29.95 |
| AVG Volume (30 Days) | ★ 5.3M | 1.3M |
| Earning Date | 03-02-2026 | 04-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.13 | ★ 467.57 |
| EPS | N/A | ★ 0.69 |
| Revenue | $723,876,000.00 | ★ $726,437,000.00 |
| Revenue This Year | $11.39 | $15.06 |
| Revenue Next Year | $8.41 | $11.34 |
| P/E Ratio | ★ N/A | $34.77 |
| Revenue Growth | 10.94 | ★ 40.45 |
| 52 Week Low | $7.15 | $14.08 |
| 52 Week High | $20.74 | $28.35 |
Technical Indicators
Market Signals| Indicator | ASAN | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 24.29 | 46.75 |
| Support Level | $7.30 | $21.51 |
| Resistance Level | $7.78 | $24.56 |
| Average True Range (ATR) | 0.55 | 0.90 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 11.93 | 51.69 |
Price Performance
Historical ComparisonAbout ASAN Asana Inc.
Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.